Search

anti vegf header

Editorial Feature:

Anti-VEGF: The Next Generation

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Show Description +

If a patient is stable only at 5-week bevacizumab (Avastin, Genentech) intervals, should you proactively upgrade to extend the interval? David Miller, MD; Esther Kim, MD; and Ehsan Rahimy, MD, examine what “success” means in the modern era, when they raise the option of using a next-generation anti-VEGF agent, and how patient preference shapes durability targets.

Posted: 11/10/2025

Keywords:

Anti-VEGF

•

Eylea

•

eylea hd

•

Regeneron Pharmaceuticals

•

Bevacizumab

•

Avastin

•

durability

Up Next

Switching From Bevacizumab to Aflibercept 8 mg in a Patient With Neovascular AMD

Switching From Bevacizumab to Aflibercept 8 mg in a Patient With Neovascular AMD

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching From Aflibercept 2 mg to Faricimab in a Patient With Newly Diagnosed Neovascular AMD and Worsening Pigment Epithelium Detachment

Switching From Aflibercept 2 mg to Faricimab in a Patient With Newly Diagnosed Neovascular AMD and Worsening Pigment Epithelium Detachment

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Conversion to Neovascular AMD in a Geographic Atrophy Patient With a 2-Year Treatment History

Conversion to Neovascular AMD in a Geographic Atrophy Patient With a 2-Year Treatment History

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

St<strike>ep</strike>upid Edits in a Neovascular AMD Patient

Stepupid Edits in a Neovascular AMD Patient

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Neovascular AMD (PCV Variant) Patient Switched to Two Different Next-generation Therapies

Neovascular AMD (PCV Variant) Patient Switched to Two Different Next-generation Therapies

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Back to All Videos

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

If a patient is stable only at 5-week bevacizumab (Avastin, Genentech) intervals, should you proactively upgrade to extend the interval? David Miller, MD; Esther Kim, MD; and Ehsan Rahimy, MD, examine what “success” means in the modern era, when they raise the option of using a next-generation anti-VEGF agent, and how patient preference shapes durability targets.

Posted: 11/10/2025

Keywords:

Anti-VEGF

•

Eylea

•

eylea hd

•

Regeneron Pharmaceuticals

•

Bevacizumab

•

Avastin

•

durability

Please log in to leave a comment.